Drug profile · INN
gilteritinib
XOSPATA
gilteritinib (XOSPATA) is a tyrosine-protein kinase receptor flt3 inhibitor. Associated with Astellas Pharma Inc.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01EX13
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — gilteritinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.83
Quick answer
gilteritinib (XOSPATA) is a tyrosine-protein kinase receptor flt3 inhibitor. Associated with Astellas Pharma Inc.
Key facts
INN gilteritinib
Brand XOSPATA
Mechanism Tyrosine-protein kinase receptor FLT3 inhibitor
Target Receptor-type tyrosine-protein kinase FLT3
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX13
Originator Astellas Pharma Inc
Mechanism of action
Tyrosine-protein kinase receptor FLT3 inhibitor
Primary target: Receptor-type tyrosine-protein kinase FLT3
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is gilteritinib?
gilteritinib (XOSPATA) is a tyrosine-protein kinase receptor flt3 inhibitor. Associated with Astellas Pharma Inc.
What is the brand name for gilteritinib?
XOSPATA is a marketed brand name for gilteritinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.